The Case For Moving Capability Building From HR To PMO
This may upset some human resources HR leaders, but I believe that for too long, capability building has been miscategorized as an HR function. Because of this, it often ends up sitting quietly in the corner of the organization, far from the action. It gets packaged as employee retention, training plans, learning management system (LMS) completions—training programs that tick boxes but don't shift performance.
But here's the uncomfortable truth I have come to realize: In project-based organizations where execution speed, delivery performance and adaptability are everything, this model of HR-run capability building isn't just outdated—it may be holding you back.
Shifting From HR To PMO
If capability is the engine of delivery, why isn't it embedded where delivery actually happens—the project management office (PMO)? My underlying rationale for this argument is that HR is designed for consistency, whereas the PMO is designed for performance.
This isn't a dig at HR. HR plays a vital role in managing workforce systems, policies and employee life cycle processes that support organizational stability, compliance and culture. But let's be honest: HR is geared for consistency and control. It's designed to support the employee life cycle, not the delivery life cycle.
The PMO, on the other hand, is designed for movement, for execution, for impact. It works at the sharp edge of strategy: turning ambition into reality through coordinated delivery. It sees firsthand where the capability bottlenecks are, which tools are underutilized and which teams are underperforming.
Capability As Both A Delivery And A Development Issue
Projects fail when skills don't match the work to be done. In complex project environments, this issue can become even more profound. In my experience, many missed milestones and blown budgets come down to one thing: The team didn't have the right capability at the right time.
And yet we still treat capability building as something separate from delivery. Teams wait for annual training plans, generic courses or slow approval processes. Meanwhile, the work keeps moving.
I believe capability building needs to be in the hands of the PMO because they are already embedded in project planning, performance tracking, milestone reviews and delivery risk management. PMO typically finds out, faster and more clearly than HR, where capability gaps are emerging and what's needed to close them.
Shifting capability building from HR to PMO may not work for everyone, but I highly recommend it if your organization is heavily tech-centric or has high digital maturity. I have found through working with my own company that embedding capability building into the PMO of a project-based organization can lead to teams being more agile, responsive and equipped with the vital skills needed for productivity transformation—particularly in increasingly complex environments. This can help you consistently deliver projects and services on time, on budget and with outcomes that matter.
Five Steps To Make The Shift For Project-Based Organizations
1. Reframe capability as a delivery asset. Stop talking about training plans and start talking about delivery enablement. Position capability as a lever for delivery excellence and not as an HR 'initiative.'
2. Relocate or co-locate the capability function. Move the capability function into the PMO. Create a dual operating model where the PMO drives delivery-focused capability while HR supports foundational and enterprise-wide needs.
3. Measure what matters. Put performance over participation: Adopt a capability measurement model that links skill growth to project performance and productivity metrics, including timelines, quality, cost and customer outcomes.
4. Build just-in-time, embedded learning infrastructure. Replace generic training with project-embedded, microcredential learning that is aligned to priority competencies. Build content libraries, enable expert coaching and create systems that deliver learning in the flow of work.
5. Build a competency-based workforce. Redesign your jobs based on the skills needed for each role, and align all roles, skills and development to clearly defined capabilities.
Utilizing AI For Just-In-Time Capability Building
AI can be one of the biggest enablers for shifting capability-building duties from HR to PMO. Forget the narrative of self-styled gurus that say AI is just the copilot to jobs; it can do so much more. It stands to totally transform jobs, not just at the periphery but across the board.
For example, earlier this year, Moderna announced its move to merge technology and HR into a single function under the CIO office to align with changes brought on by AI technology. This is just one of the latest signs that artificial intelligence is bringing big changes to the workforce.
Here are several ways you can utilize AI to help your PMO deliver in capability building:
• Use project delivery analytics for real-time capability gap detection.
• Develop and deliver role-specific expert learning content, on demand and derived from industry best practices.
• Verify and validate skills in all training and by all providers.
• Enable dynamic skills mapping and personalized learning-pathway generation, especially for capability uplift.
• Embed AI coaching within project management tools.
• Use project metrics and performance data to drive learning.
• Implement workforce capability forecasting and delivery-readiness simulation.
Final Thoughts
Let's be clear: This shift may ruffle feathers. Traditional HR and L&D leaders may see this as a land grab.
It's not. It's about recognizing that transformational capability building shouldn't be managed as a support function anymore—not when delivery is on the line. This is a call to elevate capability, not sideline HR. I believe the future is collaborative, but it's also urgent. In project-based environments, capability should be owned by those closest to the work, the performance and the results.
This shift is about repositioning capability as a strategic, embedded and responsive engine of delivery excellence. And that requires bold change. The PMO has evolved from a governance body to a strategic powerhouse. It's time to go further and make it the beating heart of organizational capability.
Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Minerals Technologies Inc. Announces Participation at Upcoming Investor Conferences
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) ('MTI') today announced its participation at two upcoming investor conferences: August 19, 2025: Seaport Research Partners' Annual Summer Conference (virtual) September 4, 2025: Jefferies' Industrials Conference (in-person in New York, NY) – Douglas T. Dietrich, Chairman and Chief Executive Officer, will present at 3:30pm ET in addition to participating in one-on-ones with individual investors. MTI will be represented by Douglas T. Dietrich, Chairman and Chief Executive Officer, Erik Aldag, Chief Financial Officer, and Lydia Kopylova, Vice President of Investor Relations, at both events. To register and for additional details and presentation materials, please visit MTI's Events & Presentations page. About Minerals Technologies Inc. New York-based Minerals Technologies Inc. is a leading, technology-driven specialty minerals company that develops, produces, and markets a broad range of mineral and mineral-based products, related systems, and services. MTI serves globally a wide range of consumer and industrial markets, including household, food and pharmaceutical, paper, packaging, automotive, construction, and environmental. The company reported global sales of $2.1 billion in 2024. For further information, please visit our website at Investor Relations ContactLydia Media ContactStephanie in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Aggreko Partners With Western Golf Association to Support Scholarships and Veterans for Second Year
As a part of the three-year partnership with WGA, Aggreko continues their support of the Evans Scholars Foundation's college scholarship program Aggreko supports 2025 BMW Championship with power solutions, veteran partnership HOUSTON, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Aggreko, a global leader in energy solutions, announces its continuing partnership with the Western Golf Association (WGA) and Evans Scholars Foundation (ESF). For the second year in a row, the company will serve as the official power provider for WGA-hosted golf championships and a supporter of the ESF's college scholarships for youth caddies. The first partnership event this year is the 2025 BMW Championship on August 12–17 at the Caves Valley Golf Club in Baltimore, Maryland, a PGA TOUR event where Aggreko will also serve as the Official Military Appreciation partner. The energy solutions company will provide both cooling and power technology for the championship event. Along with the WGA partnership, Aggreko is continuing its support of ESF with the Aggreko Power Solutions Evans Scholarship, an award that provides a full tuition and housing college scholarship to a high-achieving youth caddie. The first Aggreko Power Solutions Evans Scholar is Sean Raadsen, a University of Illinois Chicago sophomore studying Aerospace Engineering and an accomplished caddie at the Crystal Lake Country Club in his hometown of Crystal Lake, Illinois. 'Partnering with WGA and ESF has been a great honor for us, and a central part of our youth and veteran outreach,' said Stephen Saal, Vice President of Sales and Marketing at Aggreko North America. 'We are honored to continue supporting WGA events with our advanced energy solutions, as well as supporting the college scholarship program for ESF. We're also pleased to continue our work with the veteran community as the Military Appreciation Partner for the BMW Championship this year.' As the power provider for the BMW Championship, Aggreko will install and operate air conditioners and generators to fulfill the energy needs for the duration of the tournament. The company has also provided power, heating, and cooling services for previous PGA TOUR events, including THE CJ CUP Byron Nelson and the 2024 BMW Championship. Aggreko is also supporting the BMW Championship as Military Appreciation Partner, enabling all active duty, retirees, active reserve, and veterans of any branch of service to receive a complimentary ticket on each day of the championship. Military attendees and their guests will also have access to the Champions Club as the official Military Outpost hospitality tent with complimentary food and beverage on the 14th green for Tuesday and Wednesday's practice rounds. Aggreko's engagement with the BMW Championship continues the company's efforts to support the veteran population. The company actively recruits from the military population, as their expertise makes veterans highly suited to become integral members of Aggreko's workforce. For more information on the Evans Scholarship and how to apply, visit Members of the military can visit the championship's website to secure their complimentary tickets to the event. To learn more about Aggreko's programs supporting veterans and open positions at the company, visit About AggrekoAggreko is a global leader in energy solutions, providing rapidly deployable, modular power and temperature control solutions for however long they're needed. We're highly skilled sector specialists, bringing together our proprietary application know-how and engineering capability to deliver efficient, reliable and sustainable energy solutions. With experience of working in the most demanding environments, we're available for customers when they need us most, from emergency critical services to longer-term energy solutions. We're continually investing in more sustainable products, fuels and services to make greener solutions accessible to customers, helping them wherever they are on their energy transition journey. Founded in 1962, we are headquartered in the UK and employ over 6,800 people worldwide. For more information, please visit our website at Home | Aggreko. Media ContactJustin WilliamsTrevi Communications for Aggrekojustin@ (978) 539-7157 A photo accompanying this announcement is available at
Yahoo
20 minutes ago
- Yahoo
Phosphoramidite Market Set to Surpass Valuation of US$ 2.44 Billion by 2033
Explosive growth in the oligonucleotide therapeutics pipeline is driving record demand within the phosphoramidite market. Major pharmaceutical companies are responding with significant manufacturing investments to support numerous therapies advancing through late-stage clinical trials and approvals. Chicago, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The global phosphoramidite market was valued at US$ 1.21 billion in 2024 and is expected to reach US$ 2.44 billion by 2033, growing at a CAGR of 8.1% during the forecast period 2025–2033. The global phosphoramidite market is standing at the precipice of a transformative era, propelled by a powerful convergence of breakthroughs in therapeutic sciences and synthetic biology. As the foundational chemical building blocks for synthesizing DNA and RNA, phosphoramidites are central to the next generation of medicine and biotechnological innovation. The burgeoning pipeline of oligonucleotide-based drugs, coupled with accelerating advancements in genetic engineering and diagnostics, is creating a surge in demand that promises robust and sustained growth. Download Sample Pages: This report delineates the potent forces shaping this expansion, offering stakeholders a meticulously researched view of the opportunities unfolding. The sheer volume of investment, the escalating pace of clinical trials, and the strategic realignments within the industry all point towards a dynamic and highly lucrative future for the phosphoramidite market, cementing its role as a critical enabler of 21st-century life sciences. This landscape is not just growing; it is evolving, with new applications and technologies continually broadening its horizons and intensifying its commercial potential. Key Findings Phosphoramidite Market Market Forecast (2033) US$ 2.44 billion CAGR 8.1% Largest Region (2024) North America (40%) By Type DNA Phosphoramidites (37%) By Application Drug Discovery & Development (57%) By End Use Pharmaceutical & Biotechnology Companies (62%) Top Drivers Expanding pipeline of oligonucleotide therapeutics is driving significant market demand. Technological advancements in DNA synthesis are making it more accessible. Rising R&D investments by pharmaceutical and biotechnology companies fuels growth. Top Trends Increasing use of modified phosphoramidites for enhanced drug therapeutic properties. Surging interest in RNA phosphoramidites for developing mRNA therapeutics. The emergence of next-generation sequencing creates new market application frontiers. Top Challenges Manufacturing complexity of producing ultra-pure phosphoramidite reagents. Strict regulatory requirements for therapeutic-grade materials in oligonucleotide synthesis. The limited stability and shelf life of some phosphoramidite reagents. Therapeutic Pipelines Emerge as the Foremost Demand Catalyst for Growth The primary engine powering the phosphoramidite market is the spectacular rise of oligonucleotide therapeutics. These precision medicines, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), are moving from niche applications to mainstream treatment paradigms for genetic and chronic diseases. The scale of this movement is staggering; in November 2024, an estimated 12,500 drugs were in the pre-clinical research phase, a significant portion of which fundamentally rely on oligonucleotide synthesis. This preclinical activity is translating into tangible clinical progress, with over 480 active clinical trials involving oligonucleotide-based drugs recorded in 2023, primarily focused on ASO and siRNA modalities. The U.S. Food and Drug Administration (FDA) is endorsing this wave of innovation, having approved two new oligonucleotide therapeutics, imetelstat and olezarsen, in 2024 alone. The commercial outlook is equally bright, with several existing RNAi and ASO therapies like Amvuttra and Leqvio projected to achieve blockbuster status, exceeding $1 billion in annual revenue by 2030. Regulatory Endorsements and Anticipated Approvals Solidify Market Confidence The positive trajectory of the phosphoramidite market is further reinforced by a supportive regulatory environment and a clear pipeline of upcoming therapies. In a significant move in June 2024, the U.S. FDA accepted the New Drug Application for Fitusiran, a promising RNAi therapeutic designed to treat hemophilia. This signals continued confidence in the technology's potential. Looking ahead, the momentum is set to continue, with industry analysts forecasting that at least three more small nucleic acid therapies are on track for approval by the end of 2025. This steady stream of approvals not only expands the addressable patient population but also de-risks future investment in the underlying technologies and supply chains. This clear and predictable pathway to commercialization provides a stable foundation for the entire phosphoramidite market, assuring suppliers of long-term demand from a growing portfolio of life-changing medicines. The Synthetic Biology Revolution Creates New Frontiers for Demand Beyond therapeutics, the parallel explosion in synthetic biology is creating a vast and rapidly expanding new frontier for phosphoramidite consumption. This field, which focuses on engineering biological systems for novel purposes, is fundamentally dependent on high-quality, custom-synthesized DNA. The financial commitment to this sector is a testament to its potential, with private funding for synthetic biology startups projected to surge past the $5 billion mark by the end of 2024. This capital is fueling innovation across numerous applications, including personalized medicine, which itself is on track to become a major economic force, expected to generate $12 billion in revenue by the close of 2024. Technological advancements are enabling this growth; in a key development from July 2024, Ansa Biotechnologies launched its next-generation clonal DNA and DNA fragments, providing researchers with sequence-perfect DNA up to 600 base pairs long, a process that will invariably drive demand for the high-purity phosphoramidites required for such precision. North America and Europe: The Established Hubs of Innovation Geographically, North America asserted its leadership in the global phosphoramidite market in 2024, commanding a dominant 39.30% share of the landscape. This preeminence is fueled by the region's dense concentration of major pharmaceutical corporations, pioneering biotechnology firms, and world-class academic research institutions, all heavily invested in life sciences R&D. The United States market, a powerhouse within the region, was individually valued at an impressive $487.9 million in 2024, reflecting its significant consumption of phosphoramidites for both therapeutic development and fundamental research. Across the Atlantic, the United Kingdom emerged as the key revenue leader in the European market in 2024, a position solidified by substantial government investment in research and development initiatives that directly and indirectly spur demand for synthesis reagents. Asia-Pacific's Ascent Signals a Global Shift in Market Dynamics While North America currently leads, the most dynamic growth story is unfolding in the Asia-Pacific (APAC) region. Forecasts indicate that APAC is on a rapid upward trajectory, projected to become the fastest-growing region and poised to capture over 25.2% of the global market share in 2025. This accelerated growth is driven by increasing government and private sector investment in biotechnology infrastructure, a burgeoning pharmaceutical manufacturing sector, and a growing pool of scientific talent. Countries across the region are actively fostering innovation ecosystems, leading to a significant uptick in research activities related to genomics, drug discovery, and diagnostics. This regional expansion represents a critical diversification of the global phosphoramidite market, creating new logistical networks and competitive pressures that will reshape the industry's future. DNA Phosphoramidites Dominate, but RNA Synthesis Shows Fastest Growth A granular look at market segmentation reveals distinct trends by type and application. In 2024, DNA phosphoramidites stood as the dominant market segment, valued at a substantial $642.8 million. This is a direct reflection of their widespread use in diagnostics, PCR applications, and DNA sequencing. However, the segment poised for the most rapid expansion is RNA phosphoramidites, a trend directly linked to the burgeoning field of RNA therapeutics and the development of mRNA vaccines. When viewed through the lens of application, drug discovery and development was the undisputed leader in 2024, accounting for a commanding 54.14% of the total revenue share. This highlights the immense resources being poured into creating new oligonucleotide-based drugs, making it the primary value driver for the entire phosphoramidite market. Pharmaceutical Giants and Academia Drive End-User Consumption Analyzing the end-user landscape, pharmaceutical and biotechnology companies were the foremost consumers in 2024, commanding an overwhelming 61.88% of the market. This segment's dominance is projected to intensify, with forecasts suggesting it will grow into a $1.3 billion powerhouse by 2034. These commercial entities are at the forefront of translating scientific discoveries into marketable products, requiring industrial-scale quantities of phosphoramidites. Concurrently, academic and government research institutes remain a vital pillar of the phosphoramidite market, responsible for 41.3% of the revenue in 2024. These institutions conduct the foundational research that fuels the therapeutic pipeline. Within the crucial application of synthetic biology, genome engineering was the leading technology in 2024, holding a 33.86% share and serving as a key consumer of phosphoramidites for advanced genetic modifications. Strategic Investments and Collaborations Are Reshaping the Competitive Arena The industry's immense potential is attracting significant strategic investment and fostering collaborations designed to accelerate innovation. A landmark deal in June 2024 saw pharmaceutical giant GSK plc acquire Elsie Biotechnologies for $50 million, a strategic move explicitly aimed at enhancing its internal capabilities for developing sophisticated oligonucleotide-based medicines. This acquisition signals a trend of major players securing proprietary technology to gain a competitive edge. Collaborative efforts are also shaping the future of therapeutics in the phosphoramidite market. In February 2025, Biogen and Stoke Therapeutics, Inc., announced a major research collaboration to jointly develop and commercialize Zorevunersen, an investigational ASO aimed at treating Dravet syndrome. These partnerships pool resources and expertise, de-risking development and accelerating the journey of new drugs from the laboratory to the clinic, ensuring a robust and collaborative future for drug development. Request Region or Segment-Specific Customization: Regulatory Guidance and Quality Standards Ensure a Stable Future Outlook A maturing regulatory landscape and an industry-wide focus on quality are providing a stable foundation for the sustained growth of the phosphoramidite market. Recognizing the need for clarity, the FDA released a final guidance document in June 2024 titled "Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics," providing a clear roadmap for drug developers. Furthering this trend, in January 2025, key industry stakeholders began advocating for the FDA to harmonize its guidances with international standards, a move that would streamline global drug development and market access. At the product level, the pursuit of purity remains paramount. This was underscored by a 2024 patent awarded to Wave Life Sciences for an advanced synthesis method capable of achieving purity levels of 95% or more, highlighting the critical importance of quality for therapeutic efficacy and safety. This collective focus on standardization and quality excellence is crucial for building stakeholder confidence and ensuring the long-term integrity of the global supply chain. Global Phosphoramidite Market Major Players: Bioneer Biosynth Ltd BOC Sciences Creative Biolabs, Inc. Danaher Corporation Hongene Biotech Corporation Lumiprobe Corporation PolyOrg, Inc. QIAGEN N.V. Thermo Fisher Scientific Inc. Tokyo Chemical Industry (India) Pvt. Ltd. TriLink BioTechnologies Other Prominent Players Key Market Segmentation: By Type DNA Phosphoramidites RNA Phosphoramidites Labeled Phosphoramidites Modifier Phosphoramidites Others By Application Drug Discovery & Development Diagnostics Development Others By End Use Pharmaceutical & Biotechnology Companies Academic & Research Institutes Others By Region North America Europe Asia Pacific Middle East Africa South America Want Clarity on Report Coverage? Schedule a Quick Demo Call: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:
